Prognosis of patients with heart failure and reduced ejection fraction in China

Experimental and Therapeutic Medicine

Volumn 6, Issue 6, 2013, Pages 1437-1442

  Xu, Yu ^a   Shi, Yanan ^a   Zhu, Zhongyu ^a   Cui, Changhe ^a   Li, Bei ^a   Chen, Fang ^a   Li, Dan ^a   Chen, Songhu ^a   Guo, Yang ^a  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Heart failure; Left ventricular ejection fraction; Medication status quo; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; SPIRONOLACTONE; UBIDECARENONE;

ADULT; ARTICLE; BODY MASS; CHINESE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SUDDEN DEATH; SURVIVAL RATE;

EID: 84888421647     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1341     Document Type: Article

References (23)

1. Rosamond W, Flegal K, Friday G, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115: e69-e171, 2007.
2. Mendez GF and Cowie MR: The epidemiological features of heart failure in developing countries: a review of the literature. Int J Cardiol 80: 213-219, 2001.
3. World Health Organization: Cardiovascular disease: prevention and control (EB/OL). http://www.who.int/dietphysicalactivity/publications/facts/cvd/en/. Accessed March 07, 2010.
4. Cheng Z, Zhu K, Chen T, et al: Poor prognosis in chronic heart failure patients with reduced ejection fraction in China. Congest Heart Fail 18: 165-172, 2012.
5. McKee PA, Castelli WP, McNamara PM and Kannel WB: The natural history of congestive heart failure: the Framingham study. N Engl J Med 285: 1441-1446, 1971.
6. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2 Suppl 1): S1-S266, 2002.
7. Zhou B; Cooperative Meta-Analysis Group of China Obesity Task Force: Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population. Chinese Journal of Epidemiology 23: 5-10, 2002 (In Chinese).
8. Dickstein K, Cohen-Solal A, Filippatos G, et al; ESC Committee for Practice Guidelines (CPG): ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933-989, 2008.
9. Kawashiro N, Kasanuki H, Ogawa H, Matsuda N and Hagiwara N; Heart Institute of Japan-Department of Cardiology (HIJC) Investigators: Clinical characteristics and outcome of hospitalized patients with congestive heart failure: results of the HIJC-HF registry. Circ J 72: 2015-2020, 2008.
10. Cowie MR, Wood DA, Coats AJ, et al: Survival of patients with a new diagnosis of heart failure: a population based study. Heart 83: 505-510, 2000.
11. Stewart S, MacIntyre K, Hole DJ, Capewell S and McMurray JJ: More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 3: 315-322, 2001.
12. Ho KK, Anderson KM, Kannel WB, Grossman W and Levy D: Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88: 107-115, 1993.
13. Senni M, Tribouilloy CM, Rodeheffer RJ, et al: Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 159: 29-34, 1999.
14. Levy WC, Mozaffarian D, Linker DT, et al: The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 113: 1424-1433, 2006.
15. McDonagh TA, Cunninghanl AD, Morrison CE, et al: Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86: 21-26, 2001.
16. Hartmann F, Packer M, Coats AJ, et al: Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110: 1780-1786, 2004.
17. Doust JA, Pietrzak E, Dobson A and Glasziou P: How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330: 625, 2005.
18. Zamora E, Lupón J, de Antonio M, et al: The obesity paradox in heart failure: Is etiology a key factor? Int J Cardiol 166, 601-605, 2013.
19. No authors listed: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001-2007, 1999.
20. No authors listed: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 353: 9-13, 1999.
21. Packer M, Fowler M and Rouleau J, et al: COPERNICUS (carvedilol prospective randomized cumulative survival trial): A multicenter randomized double-blind placebo-controlled study to determine the effect of carvedilol on mortality in severe congestive heart failure. Cardiovasc Drugs Ther 13: 24, 1999.
22. Society of Cardiology, Chinese Medical Association: Retrospective investigation of hospitalized patients with heart failure in some parts of China in 1980, 1990 and 2000. Chinese Journal of Cardiology 30: 450-454, 2002 (In Chinese).
23. Cao YM, Hu DY, Wang HY and Wu Y: A survey of medical therapies for chronic heart failure in primary hospitals in China. Chinese Journal of Internal Medicine 45: 907-909, 2006 (In Chinese).